Full-Time

Senior / Staff Automation Engineer

Posted on 12/17/2024

Insitro

Insitro

201-500 employees

Machine learning for drug discovery efficiency

Compensation Overview

$165k - $215k/yr

+ Annual Performance Bonus + Equity Incentive Plan

Senior, Expert

San Bruno, CA, USA

Onsite role expected to be in the office at least 4 days/week in South San Francisco Headquarters.

Category
Bioinformatics
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Python
SQL
C#
Requirements
  • Bachelor's degree or higher in Robotics, Mechanical, Electrical, Chemical, Software or Bioengineering, or Physics, Chemistry or Biology
  • B.S, with 8+ years, M.S with 6+ years, or Ph.D. with 3+ years of professional experience working with automation hardware
  • Experience automating scientific workflows (ex. Cell Culture, Genomic Screening or DNA-encoded Library processes)
  • Experience working with Python, SQL, and/or C#
  • Comfortable completing work independently on complex projects and can also give guidance to others on daily work
  • Experience managing the relationship to other engineering functions (eg. third party service providers and vendors or internal mechanical or software engineering teams)
  • Understanding existing capabilities of the lab automation industry and a track record showing technical depth in automation systems of varying scale.
Responsibilities
  • Come up to speed on various scientific process to drive the translation of workflows onto automation systems
  • Design, develop and qualify new workcells and liquid handling protocols to enable new platform capabilities
  • Work with the Automation Industrialization team to ensure equipment is in good operating condition and troubleshoot automation or software errors
  • Work with the Automation Sciences team to define scientific workflows, develop process specific QC metrics, and ensure successful transfer of methods to end users
  • Collaborate with folks from our machine learning, software engineering and scientific groups to solve questions ranging from technology onboarding, minimizing batch effects, or process improvements
  • Identify opportunities in how we develop, test and deploy automation solutions more efficiently
  • Lead and shape our team culture with your ideas and experience
  • Collaborate with the LIMS team on workflow parametrization

Insitro focuses on drug discovery and development in the pharmaceutical research sector. The company utilizes machine learning and biological tools to predict which paths are likely to lead to successful medicines, aiming to minimize the costly failures often seen in drug R&D. By integrating machine learning with biology, Insitro creates predictive models that help avoid unproductive routes in the drug discovery process. Their team, made up of scientists, engineers, and drug hunters, collaborates to generate and use data to advance new medicines. Insitro primarily serves pharmaceutical companies, healthcare providers, and research institutions seeking more efficient drug development methods. The company likely generates revenue by selling predictive models and insights or through partnerships with other pharmaceutical firms to co-develop drugs. Insitro's goal is to enhance the efficiency and effectiveness of pharmaceutical R&D through data-driven approaches.

Company Size

201-500

Company Stage

Series C

Total Funding

$643M

Headquarters

San Francisco, California

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Insitro received $25 million from Bristol Myers Squibb for ALS target discovery.
  • The company raised over $600 million in venture capital funding.
  • Insitro appointed AI expert Emily Fox as Senior VP of AI/ML.

What critics are saying

  • Competition from well-funded companies like Xaira Therapeutics challenges Insitro's market position.
  • Ethical concerns in AI drug development may affect Insitro's public perception.
  • Data privacy issues could lead to regulatory challenges for Insitro.

What makes Insitro unique

  • Insitro integrates machine learning with high-throughput biology for drug discovery.
  • The company builds predictive models to accelerate target selection and drug development.
  • Insitro's team combines expertise in science, engineering, and drug discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Excellent medical, dental, and vision coverage

Excellent mental health and well-being support

Open vacation policy

Access to free onsite baristas & cafe with daily lunch and breakfast

Access to free onsite fitness center

Commuter benefits

Paid parental leave

Competitive pay and 401(k) matching

Flexible work schedule (on site and remote)

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

4%
Business Wire
Dec 18th, 2024
insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS

insitro receives $25 million in milestone payments from Bristol Myers Squibb for the achievement of discovery milestones and the selection of first novel genetic target for ALS.

Stock Titan
Dec 18th, 2024
insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS

insitro receives $25 million in milestone payments from Bristol Myers Squibb for the achievement of discovery milestones and the selection of first novel genetic target for ALS.

San Diego Business Journal
Jul 1st, 2024
Iambic Raises $153 Million Series B

Other competitors in the biotech space that use AI include Xaira Therapeutics, which has raised over $1 billion in funding and San Fransico-based Insitro, which has raised over $600 million in venture capital funding.

Business Wire
Apr 30th, 2024
Insitro Hires Ai And Machine Learning Visionary, Emily Fox, Ph.D., As Senior Vice President Of Ai/Ml

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, a machine learning-powered drug discovery and development company, today announced the appointment of Emily Fox, Ph.D., as senior vice president of AI/machine learning. In this role, she will oversee those areas as well as data science and computational biology, inclusive of data modalities that span genetics, omics, imaging, clinical data, and molecular design. Dr. Fox, a professor in the Department of Statistics and Department of Computer Science at Stanford University, has made groundbreaking contributions in the application of machine learning in healthcare, with her pioneering work directly translating into patient impact. "AI leaders of Emily’s caliber who simultaneously have an understanding of biology and health are rare, and we are privileged to have recruited her to lead our AI/ML teams,” said Daphne Koller, Ph.D., co-founder and CEO. “Her groundbreaking work in machine learning, alongside her track record in translating research into impactful applications in healthcare, aligns perfectly with our mission to revolutionize drug discovery through data-driven approaches

Elk Valley Times
Apr 4th, 2024
Leading Clinical Research Innovator, Amy Abernethy, M.D., Ph.D., Joins insitro Board of Directors

insitro, a machine learning-powered drug discovery and development company, today announced that Amy Abernethy, M.D., Ph.D, has joined the company's board of directors.

INACTIVE